Lancet Psychiatry
May 17, 2016
Robin L Carhart-Harris, Mark Bolstridge, James Rucker et al.
1,546 citations
In an open-label trial, 12 patients with moderate-to-severe treatment-resistant depression received two doses of psilocybin (10 mg and 25 mg, one week apart) in a supportive setting. The psychedelic effects peaked 2-3 hours after dosing and subsided within 6 hours. No serious adverse events occurred; transient anxiety, confusion, nausea, and headache were noted. Depressive symptoms, measured with the Quick Inventory of Depressive Symptoms, were markedly reduced one week after the high dose (mean reduction of 11.8 points) and remained lower at three months (mean reduction of 9.2 points). Improvements in anxiety and anhedonia were also observed. The results provide preliminary support for psilocybin's safety and efficacy in treatment-resistant depression, warranting further controlled trials.
Lancet Psychiatry
May 1, 2018
Michael C Mithoefer, Ann T Mithoefer, Allison A Feduccia et al.
443 citations
A randomized, double-blind, phase 2 clinical trial tested MDMA-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers. Participants were randomly assigned to receive different doses of MDMA during psychotherapy sessions. The findings revealed that the active dose of MDMA led to significant and lasting reductions in PTSD symptoms compared to the lower dose, indicating that this innovative therapeutic approach can effectively treat this condition and provide significant relief for individuals with profound trauma.
Lancet Psychiatry
April 5, 2016
Michael C Mithoefer, Charles S Grob, Timothy D Brewerton
237 citations
Psilocybin and MDMA are emerging as novel psychopharmacological therapies for psychiatric disorders, offering potential alternatives to conventional treatments. These substances are being investigated for their ability to facilitate therapeutic breakthroughs in conditions such as depression and post-traumatic stress disorder. The text outlines their mechanisms, clinical applications, and the growing interest in their use within mental healthcare. It highlights the need for further research to establish safety and efficacy, while acknowledging the promise these therapies hold for addressing treatment-resistant psychiatric conditions.
Lancet Psychiatry
April 5, 2017
Ilina Singh, Celia Morgan, Valerie Curran et al.
158 citations
Ketamine offers fast-acting antidepressant effects for severe depression, presenting opportunities for clinical innovation and new treatment models. However, its powerful intervention requires robust ethical guidelines to ensure it is responsibly delivered and widely accessible, prioritizing patient well-being. The work advocates for ethical foresight alongside clinical advancement, framing ketamine as a beacon of hope that demands careful oversight to maximize benefits and minimize risks.
Lancet Psychiatry
October 1, 2020
Brian T Anderson, Alicia L Danforth, Charles S Grob
99 citations
The text discusses safety and ethical concerns surrounding psychedelic medicine, emphasizing the need for stringent oversight, comprehensive patient screening, robust therapeutic support, and informed consent to mitigate risks such as psychological distress and misuse. It highlights the ethical imperative for equitable access and responsible medical use as these powerful medicines are integrated into clinical practice.
Lancet Psychiatry
September 1, 2016
Robin L Carhart-Harris, David J Nutt
1 citation
No Summary